FDA Approved EPIDIOLEX® (Cannabidiol) for Epilepsy

 

June 25, 2018:

FDA approved EPIDIOLEX® (Cannabidiol) oral solution for treatment of seizures associated with:

  1. Lennox-Gastaut syndrome and

  2. Dravet syndrome.

in patients 2 yr and older. 

 


What is EPIDIOLEX® (Cannabidiol)?

This is pharmaceutical formulation of highly-purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the high associated with marijuana.

 


Novel Mechanism of Action in Epilepsy:

  • CBD does not act through cannabinoid (CB) receptors or sodium channels.
  • Prime targets are GPR55 and adenosine reuptake, TRPV1.

 


Positive Studies Behind this FDA Approval:

 

(1) Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet , Volume 391 , Issue 10125 , 1085 – 1096.

  • Randomised, double-blind, placebo-controlled trial done at 24 clinical sites in the USA, the Netherlands, and Poland.
  • This study investigated the efficacy of cannabidiol as add-on therapy for drop seizures in patients with treatment-resistant Lennox-Gastaut syndrome.
  • Age: 2–55 years.
  • n= 171: randomized to receive cannabidiol (n=86) or placebo (n=85).
  • Patients had not responded to treatment with at least two antiepileptic drugs.
  • Active group received 20 mg/kg oral cannabidiol daily for 14 weeks.
  • Median % reduction in monthly drop seizure frequency from baseline: 43·9% (IQR −69·6 to −1·9) in the cannibidiol group and 21·8% (IQR −45·7 to 1·7) in the placebo group. 
  • Adverse events: 74 (86%) of 86 patients in the cannabidiol group and 59 (69%) of 85 patients in the placebo group; most were mild or moderate.
  • The most common adverse events were diarrhoea, somnolence, pyrexia, decreased appetite, and vomiting. 

 

(2) Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376;2011-20.

  • Double-blind, placebo-controlled trial.
  • n= 120 (61 = received cannabidiol; 59 = placebo).
  • Age = 2 to 18 years.
  • Active group received 20 mg/kg oral cannabidiol daily.
  • 14-week treatment period (2 weeks of dose escalation and 12 weeks of dose maintenance).
  • Median frequency of convulsive seizures per month: decreased from 12.4 to 5.9 with cannabidiol, as compared with a decrease from 14.9 to 14.1 with placebo.
  • The percentage of patients who had at least a 50% reduction in convulsive-seizure frequency was 43% with cannabidiol and 27% with placebo (odds ratio, 2.00; 95% CI, 0.93 to 4.30; P=0.08).
  • The percentage of patients who became seizure-free was 5% with cannabidiol and 0% with placebo (P=0.08).
  • Adverse events: diarrhea, vomiting, fatigue, pyrexia, somnolence, and abnormal results on liver-function tests. 

 

(3) Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome. N Engl J Med 2018;378;20:1888-97.

  • Double-blind, placebo-controlled trial conducted at 30 clinical centers.
  • n = 225 (76 = 20mg cannabidiol group; 73 = 10mg cannabidiol group; 76 = placebo group).
  • Age = 2 to 55 years.
  • Duration of treatment = 14 weeks.
  • The median % reduction from baseline in drop-seizure frequency during the treatment period was: 41.9% in the 20-mg cannabidiol group, 37.2% in the 10-mg cannabidiol group, and 17.2% in the placebo group (P=0.005 for the 20-mg cannabidiol group vs. placebo group, and P=0.002 for the 10-mg cannabidiol group vs. placebo group).
  • The most common adverse events among the patients in the cannabidiol groups were somnolence, decreased appetite, and diarrhea.
  • These events occurred more frequently in the higher-dose group.
  • 14 patients who received cannabidiol (9%) had elevated liver aminotransferase concentrations.

 


COMMON ADVERSE EFFECTS:

Based on above trials results:

  • GI: diarrhea, decreased appetite, and vomiting.
  • Abnormal liver function test.
  • Neuro: somnolence.
  • Others: pyrexia, fatigue.

NOTE: These adverse events risk increases at high doses.

 


Source:

  1. http://ir.gwpharm.com/static-files/e7afbad8-ab2c-4c8a-8e21-b9d3a7d36c70.
  2. FDA Approves First Cannabis Drug for Rare Forms of Epilepsy – Medscape – Jun 25, 2018.

Please do post your questions or comments below. 


Dr. Harvinder Singh, M.D. (Admin)


Enroll in our online course to have access to all important clinically relevant psychiatry topics in one place.


Related Articles